尽管阿斯利康的抗癌药物销售强劲，但其股价还是下跌。 AstraZeneca's share price fell down despite posting strong sales for cancer drug.

周四上午，在公布最新财务业绩后，阿斯利康 (AstraZeneca) 股价在伦敦证券交易所下跌近 4%。 Shares in AstraZeneca were down nearly 4% on the London Stock Exchange on Thursday morning after reporting its latest financial results. 这家英瑞生物制药公司公布 2023 财年收入为 458 亿美元（约合 417 亿欧元），并强调其抗癌药物销售强劲。 The Anglo-Swedish biopharmaceutical company reported $45.8bn (around €41.7bn) in revenue for the financial year 2023 and highlighted strong sales for its cancer drug. 它还公布了超过 375 亿美元（约合 340 亿欧元）的毛利润，高于 2022 年的 320 亿美元（约合 290 亿欧元）。 It also posted a gross profit of more than $37.5bn (around €34bn), up from $32bn (around €29bn) in 2022.